Drug repositioning

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Drug repositioning (AKA drug repurposing) involves the investigation of existing drugs for new therapeutic purposes.[1][2]

A number of successes have been achieved, the foremost including sildenafil (Viagra) for erectile dysfunction and pulmonary hypertension and thalidomide for leprosy and multiple myeloma.[2][3] Clinical trials have been performed on posaconazole and ravuconazole for Chagas disease. Other antifungal agents clotrimazole and ketoconazole have been investigated for anti-trypanosome therapy.[4]


  1. ^ Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
  2. ^ a b Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734.
  3. ^ Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3.
  4. ^ Gambino, Dinorah; Otero, Lucia (2019). "Chapter 13. Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic". In Sigel, Astrid; Freisinger, Eva; Sigel, Roland K. O.; Carver, Peggy L. (Guest editor) (eds.). Essential Metals in Medicine:Therapeutic Use and Toxicity of Metal Ions in the Clinic. Metal Ions in Life Sciences. 19. Berlin: de Gruyter GmbH. pp. 331–357. doi:10.1515/9783110527872-019. ISBN 978-3-11-052691-2. PMID 30855114.Section 2.2.2. "Repositioning of Drugs"

Further reading[edit]